Skip to content
Catalyst

PapersPMID:38570276

Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration.

Neurotherapeutics2024The record ↗

  1. Finding, insufficient evidencelowersNLRP3

What moved

1 findingHow to read these marks →
  • Inhibits NLRP3

    insufficient

    “The qRT-PCR results showed that BBR dose-dependently inhibited the mRNA expression of NLRP3 and its linked molecules, including IL-1β, caspase-1, ASC, and GSDMAD.”
    Study
    animal · not in humans
    Duration
    4 weeks
    Dose studied
    60-240 mg/kg/day, daily oral gavage, days 1-28
    Population
    C57BL/6J mice with sciatic nerve crush injury (peripheral nerve injury), injury-site tissue

Study record

Design
animal study, in vivo
Species
animal / mixed
Population
C57BL/6J mice, male and female, sciatic nerve crush (peripheral nerve injury) model
Participants
not reported
Comparator
another dose
Duration
28 days
Endpoints measured
6